Replies to post #679 on Argos Therapeutics Inc fka ARGSQ

[Klinsmann]

Rocapuldencel-T mRCC • Ongoing ADAPT trial; enrollment completed in July 2015; IDMC recommended study discontinuation; plan to continue until at least the pre-specified number of 290 events occurs, anticipated in the first half of 2018; plan to submit to the FDA a protocol amendment to increase the pre-specified number of events beyond 290 events; data analysis and discussions with the FDA ongoing

• Planned Phase 2 clinical trial, in combination with a checkpoint inhibitor, expected to open for enrollment in the second half of 2017 provided that financing is obtained

Early stage RCC (neoadjuvant) • Ongoing investigator-initiated Phase 2 clinical trial; initial data expected in 2017

Advanced solid tumors • Planned investigator-initiated Phase 2 clinical trial in muscle invasive bladder cancer, expected to open for enrollment in the second half of 2017 provided that financing is obtained

AGS-004 HIV • Ongoing second stage of investigator-initiated clinical trial in combination with vorinostat for HIV eradication

• Decision to open planned investigator-initiated Phase 2 clinical trial for long-term viral control in pediatric patients expected in 2017

[declaes]

sorry wrong board...oeps

ARGS will ask for an extension of 180 days. If they can't get one they will appeal and have at least another 30 days. Expecting news about this soon.

"If the Company does not regain compliance with the Bid Price Requirement by the Bid Price Compliance Date and is not eligible for an additional compliance period at that time, the Staff will provide written notification to the Company that its common stock may be delisted. At that time, the Company may appeal the Staff’s delisting determination to the Panel. The Company expects that its common stock would remain listed pending the Panel’s decision. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by the Staff to the Panel, such appeal would be successful.

The Company expects to regain compliance with the Audit Committee Requirement by the Audit Committee Compliance Date. If the Company does not regain compliance with the Audit Committee Requirement by the Audit Committee Compliance Date, the Staff will provide written notification to the Company that its common stock may be delisted. At that time, the Company may appeal the Staff’s delisting determination to the Panel. The Company expects that its common stock would remain listed pending the Panel’s decision. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by the Staff to the Panel, such appeal would be successful."

[TheShadow]

Not sure where you get that date. Everything is in the filings for all to read.
It's simple DD.
https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12221604

We are required to meet specified requirements to maintain our listing on The NASDAQ Global Market, including, among other things, a minimum $50,000,000 market value of listed securities, a minimum bid price of $1.00 per share and an audit committee that is comprised of at least three members, each of whom is independent.



On April 28, 2017, we received a deficiency letter from the Listing Qualifications Department, or the Staff, of The NASDAQ Stock Market notifying us that we are not in compliance with the minimum $50,000,000 market value of listed securities requirement for continued listing on The NASDAQ Global Market.
We have been provided a period of 180 calendar days, or until October 25, 2017, to regain compliance with the market value of listed securities requirement. If, at any time before October 25, 2017, the market value of our common stock closes at $50,000,000 or more for a minimum of 10 consecutive business days, we may be eligible to regain compliance with the market value of listed securities requirement. If we do not regain compliance with the market value of listed securities requirement, the Staff will notify us that our common stock may be delisted.


Quote: On May 2, 2017, we received another deficiency letter from the Staff notifying us that, for the previous 30 consecutive business days, the bid price for our common stock had closed below the minimum $1.00 per share requirement for continued inclusion on The NASDAQ Global Market. We have been provided an initial period of 180 calendar days, or until October 30, 2017, to regain compliance with the minimum bid price requirement. If, at any time before October 30, 2017, the bid price for our common stock closes at $1.00 or more for a minimum of 10 consecutive business days, we may be eligible to regain compliance with minimum bid price requirement. If we do not regain compliance by October 30, 2017, we may be eligible for an additional 180 calendar day compliance period, provided that we transfer the listing of our common stock to The NASDAQ Capital Market. If we do not regain compliance by October 30, 2017 and we are not eligible for an additional compliance period at that time, the Staff will notify us that our common stock may be delisted.



Also, on May 2, 2017, we received another deficiency letter from the Staff notifying us that we are not in compliance with the requirement that a listed company’s audit committee be comprised of at least three members, all of whom are independent. Our non-compliance with this requirement occurred upon the resignation of Ralph Snyderman, M.D. as a member of our Board of Directors and our Audit Committee, on March 31, 2017. The Staff provided us a cure period to regain compliance: (i) until the earlier of our next annual stockholders' meeting or April 2, 2018, or (ii) if the next annual stockholders’ meeting is held before September 27, 2017, then we must evidence compliance no later than September 27, 2017. If we do not, the Staff will notify us that our common stock may be delisted.



In addition, on May 9, 2017, we received a deficiency letter from the Staff notifying us that we are not in compliance with the minimum $15,000,000 market value of publicly held shares requirement for continued listing on The NASDAQ Global Market. We have been provided a period of 180 calendar days, or until November 6, 2017, to regain compliance with the market value of publicly held shares requirement. If, at any time before November 6, 2017, the market value of our common stock closes at $15,000,000 or more for a minimum of 10 consecutive business days, we may be eligible to regain compliance with the market value of publicly held shares requirement. If we do not regain compliance with the market value of publicly held shares requirement, the Staff will notify us that our common stock may be delisted.



If our common stock is delisted by NASDAQ, our common stock may be eligible to trade on the OTC Bulletin Board or another over-the-counter market. Any such alternative would likely result in it being more difficult for us to raise additional capital through the public or private sale of equity securities and for investors to dispose of, or obtain accurate quotations as to the market value of, the common stock and could result in a decrease in the trading price of our common stock. We may also face other material adverse consequences in such event, such as negative publicity, a decreased ability to obtain additional financing, diminished investor and/or employee confidence, and the loss of business development opportunities, some or all of which may contribute to a further decline in our stock price. In addition, there can be no assurance that the common stock would be eligible for trading on any such alternative exchange or markets.